Takeda Pharmaceutical Company Limited (NYSE:TAK) Short Interest Down 26.5% in April

Takeda Pharmaceutical Company Limited (NYSE:TAK) saw a significant drop in short interest in April. As of April 15th, there was short interest totalling 5,970,000 shares, a drop of 26.5% from the March 31st total of 8,120,000 shares. Currently, 0.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,850,000 shares, the short-interest ratio is currently 3.2 days.

Takeda Pharmaceutical Price Performance

Shares of Takeda Pharmaceutical stock traded down $0.04 during trading on Friday, reaching $13.03. The company’s stock had a trading volume of 1,213,476 shares, compared to its average volume of 1,688,482. The stock has a 50-day moving average price of $14.06 and a two-hundred day moving average price of $14.20. The stock has a market capitalization of $41.24 billion, a P/E ratio of 19.74, a price-to-earnings-growth ratio of 2.98 and a beta of 0.53. The company has a current ratio of 1.06, a quick ratio of 0.55 and a debt-to-equity ratio of 0.64. Takeda Pharmaceutical has a one year low of $13.01 and a one year high of $17.11.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Thursday, February 1st. The company reported $0.51 earnings per share for the quarter. The firm had revenue of $7.52 billion during the quarter. Takeda Pharmaceutical had a net margin of 6.90% and a return on equity of 12.57%. As a group, sell-side analysts anticipate that Takeda Pharmaceutical will post 1.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Takeda Pharmaceutical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TAK. NBC Securities Inc. increased its position in shares of Takeda Pharmaceutical by 1.8% in the 1st quarter. NBC Securities Inc. now owns 43,539 shares of the company’s stock valued at $614,000 after buying an additional 765 shares in the last quarter. Sage Rhino Capital LLC lifted its holdings in shares of Takeda Pharmaceutical by 7.6% during the 3rd quarter. Sage Rhino Capital LLC now owns 11,751 shares of the company’s stock valued at $182,000 after purchasing an additional 831 shares in the last quarter. Legacy Wealth Asset Management LLC grew its position in shares of Takeda Pharmaceutical by 0.7% in the 3rd quarter. Legacy Wealth Asset Management LLC now owns 124,967 shares of the company’s stock valued at $1,933,000 after purchasing an additional 851 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in shares of Takeda Pharmaceutical by 0.7% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 130,904 shares of the company’s stock valued at $1,818,000 after purchasing an additional 857 shares during the period. Finally, Vestmark Advisory Solutions Inc. increased its stake in Takeda Pharmaceutical by 1.4% during the 3rd quarter. Vestmark Advisory Solutions Inc. now owns 63,630 shares of the company’s stock worth $984,000 after purchasing an additional 870 shares in the last quarter. Institutional investors own 9.17% of the company’s stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.